<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124123</url>
  </required_header>
  <id_info>
    <org_study_id>BILA 2909/BA</org_study_id>
    <secondary_id>2010-019049-25</secondary_id>
    <nct_id>NCT01124123</nct_id>
  </id_info>
  <brief_title>Oral Bioavailability of Bilastine</brief_title>
  <acronym>BIOBI</acronym>
  <official_title>Study to Assess Oral Bioavailability of Bilastine (Estudio de Biodisponibilidad Oral de Bilastina)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faes Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faes Farma, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the absolute bioavailability of an oral bilastine
      formulation (test drug) compared to the endovenous administration of an IV bilastine
      formulation (control drug) in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, open label, cross-over, randomised, controlled, single dose study. The primary
      endpoint is the determination of plasma concentrations versus time (17 samples per subject at
      various time intervals after dosing) in order to assess the oral bioavailability of bilastine
      in healthy volunteers. Therefore the primary pharmacokinetic variable will be the area under
      the plasma concentration versus time curve from time zero to infinity (AUC 0-∞). Additionally
      the following pharmacokinetic variables will also be assessed: Cmax, AUC 0-t, tmax, Ae, Clr,
      t1/2. Additional objectives are to describe the safety and tolerability of a single
      administration of oral and endovenous bilastine in healthy volunteers.

      Twelve healthy volunteers will be included. Each volunteer will take in random order one
      single dose of 20 mg oral bilastine and 10 mg IV bilastine with a minimum washout period of
      14 days between them.

      Bilastine plasma concentrations will be measured using a liquid chromatography/mass mass
      spectrometry (LC/MS/MS) micro method
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the plasma concentration versus time curve from time zero to infinity (AUC 0-∞ ).</measure>
    <time_frame>17 blood draws performed at: 0,25 - 0,5- 0,75 - 1 - 1,25 - 1,5 - 1,75 - 2 - 2,5 - 3 - 4 - 5 - 7 - 12 - 24 - 48 and 72 hours post administration.</time_frame>
    <description>Bilastine bioavailability will be obtained from the oral AUC 0-∞ / endovenous AUC 0-∞ quotient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional pharmacokinetic variables: Cmax, AUC 0-t, tmax, Ae, CLr and t ½</measure>
    <time_frame>17 blood draws and urine collection during 72 hours post administration</time_frame>
    <description>Cmax: Maximum plasma concentration; the highest concentration observed during a dosage interval
tmax: The time that Cmax was observed
AUC 0-t: The area under the plasma concentration versus time curve from time zero to the last time point
Ae: amount of accumulated unaltered drug in urine till the last time point
Clr: Renal clearance
t ½: Elimination halflife</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of a single dose administration of oral and endovenous bilastine</measure>
    <time_frame>A last Follow up visit will be performed 7 days after last drug intake</time_frame>
    <description>Safety will be assessed during the study by monitoring adverse events (AEs), clinical laboratory test results (urinalysis, blood chemistry, and haematology), vital signs (including blood pressure, respiration, temperature, and heart rate, supine and standing), electrocardiogram (ECG) results, and abnormal findings upon physical examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Bilastine 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 20 mg bilastine oral tablet. Test drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilastine 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 10 mg Bilastine endovenous. Control drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine</intervention_name>
    <description>20 mg oral tablet</description>
    <arm_group_label>Bilastine 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine</intervention_name>
    <description>10 mg endovenous bilastine</description>
    <arm_group_label>Bilastine 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers of either sex aged from ≥ 18 to ≤ 35 years of age.

          -  Body mass index between 19 and 29 Kg/m2.

          -  Non smokers.

          -  Judged to be in general good health based on medical history, physical examination and
             clinical laboratory tests.

          -  Able to communicate well with the investigator and to comply with the requirements of
             the entire study.

          -  Provision of written informed consent to participate.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women or with a positive pregnancy test. Subjects who do
             not agree to use an adequate method of contraception during the study.

          -  Intake of another investigational medication in another clinical study within 4 months
             prior to the first study drug intake.

          -  Regular use of any prescribed medication including medicinal herbs or OTC medication
             within 4 weeks of dosing.

          -  A QTc&gt; 430 ms in males and a QTc&gt; 450 ms in females. A HR &lt;55 bpm.

          -  Existence of any surgical or medical condition which, in the judgement of the
             investigator, might interfere with the absorption, distribution, metabolism or
             excretion of the IMP.

          -  Known allergy/hypersensitivity to the study drug or its inactive ingredients.

          -  Any clinical conditions or circumstances that in the opinion of the investigator would
             make the subject unsuitable for the study (e.g., hepatic impairment, renal impairment,
             mental impairment, cardiac disease).

          -  Presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) or HIV
             1 or HIV 2 antibodies at screening.

          -  Subjects who have taken metabolic or transporter inducers/inhibitors during the 3
             months prior to inclusion in the study.

          -  Donation or loss of greater than 200 mL of blood within 12 weeks before entry to the
             study.

          -  Blood transfusion within the prior 6 months to inclusion.

          -  Ingestion of citrus fruits and cranberries or any fruit juice within 7 days prior to
             first dose of study medication.

          -  Known current alcohol or drug abuse.

          -  Excessive consumption of xanthine containing foods or drinks.

          -  Mentally disabled subjects or subjects who by official order have been
             institutionalised must be excluded from participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belen Sadaba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Investigacion Clinica. Clinica Universidad Navarra (CUN)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad de Investigacion Clinica. Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cun.es/nc/la-clinica/investigacion/ensayos-clinicos/</url>
    <description>Clinical Trials and Medical Research page. Clinica Universidad Navarra (CUN)</description>
  </link>
  <link>
    <url>http://www.cun.es/la-clinica/servicios-medicos/farmacologia/</url>
    <description>Clinical Pharmacology Department. Clinica Universidad Navarra (CUN)</description>
  </link>
  <reference>
    <citation>Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009;48(8):543-54. doi: 10.2165/11317180-000000000-00000.</citation>
    <PMID>19705924</PMID>
  </reference>
  <reference>
    <citation>Lucero ML, Gonzalo A, Ganza A, Leal N, Soengas I, Ioja E, Gedey S, Jahic M, Bednarczyk D. Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:8-17. doi: 10.3109/01480545.2012.682653. Erratum in: Drug Chem Toxicol. 2012 Oct;35(4):472.</citation>
    <PMID>22616811</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Oral bioavailability</keyword>
  <keyword>absorption</keyword>
  <keyword>AUC</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Bioavailability study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

